Skip to content
Review Open access

Wearable Cardioverter-Defibrillator in Patients at Transient Risk of Sudden Cardiac Death: State of the Art and Contemporary Clinical Evidence

Sep 2026 · Diagnostics · Vol 16 · 0 citations · 81 references
Medicine

TL;DR

Overall, current evidence supports the technical efficacy of the WCD for terminating sustained ventricular tachyarrhythmias, but observational shock rates do not establish a population-level survival benefit.

Abstract

Sudden cardiac death remains a major mode of cardiovascular mortality, yet the risk is neither constant over time nor adequately represented by left ventricular ejection fraction alone. The weeks after myocardial infarction and the early months after a new diagnosis of cardiomyopathy or acute myocarditis create arrhythmic vulnerability, and recovery with revascularization, guideline-directed medical therapy, rhythm control, or resolution of inflammation may render immediate implantable cardioverter-defibrillator implantation unnecessary or inappropriate. The wearable cardioverter-defibrillator (WCD) was developed to bridge this interval by providing non-invasive, continuously available detection and shock therapy for sustained ventricular tachyarrhythmias. The only randomized trial, VEST, did not significantly reduce arrhythmic death in the intention-to-treat analysis, and therefore does not support indiscriminate WCD prescription after myocardial infarction. Conversely, large registries and contemporary meta-analyses consistently document successful termination of malignant ventricular arrhythmias, clustering of events during the first weeks, and frequent subsequent recovery of systolic function. Economic models from several healthcare systems suggest that WCD use may be cost-effective in selected settings, although estimates are highly dependent on assumptions regarding baseline arrhythmic risk, treatment effectiveness, adherence, and healthcare-system costs, and several analyses have incorporated exposure-based VEST estimates or manufacturer involvement. Overall, current evidence supports the technical efficacy of the WCD for terminating sustained ventricular tachyarrhythmias, but observational shock rates do not establish a population-level survival benefit. The most defensible contemporary role of the WCD is therefore as a selective bridge-to-decision strategy in patients with transient or evolving arrhythmic risk, integrating not only LVEF but also substrate, arrhythmic triggers, timing, and clinical trajectory.

Read PDF

Similar papers

Open access Aug 2026

Clinical Impact of Arrhythmias Detected by an Implantable Cardiac Monitoring Device With Real-Time Transmission Among Patients With Early Reduced Left Ventricular Ejection Fraction After ST-Segment Elevation Acute Myocardial Infarction: The TeVeO Study.

BACKGROUND Modern therapeutic strategies have reduced mortality after a ST-segment elevation acute myocardial infarction (STEMI). However, up-to-date information on the incidence and prognostic impact of arrhythmias following this event is lacking. OBJECTIVES This study sought to evaluate the incidence and clinical i...

J. Jiménez-Candil, J. Hernández-Hernández, C. González-Juanatey et al. · 0 citations
Review Sep 2026

All-cause mortality and appropriate implantable cardioverter-defibrillator shocks with first-line catheter ablation versus antiarrhythmic drugs in ischemic ventricular tachycardia: A systematic review and Meta-analysis of randomized controlled trials.

In antiarrhythmic-naïve patients with ischemic cardiomyopathy and VT, first-line catheter ablation reduced appropriate ICD shocks but did not demonstrate a statistically significant reduction in all-cause mortality.

Diego Garnica, H. Bautista-Mier, R. Isaac et al. · 0 citations
Open access Sep 2026

Electrocardiographic and Clinical Determinants of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention for Ischemic and Non-Ischemic Cardiomyopathy

Introduction. Implantable cardioverter-defibrillators (ICDs) have been shown to reduce mortality in patients with both ischemic and non-ischemic cardiomyopathy (NICMP) by effectively terminating life-threatening ventricular arrhythmias. However, the distribution of ventricular arrhythmias varies across patient subgroup...

H. A. Z. Nassir, H. A. Swaid, A. Ibrahim · 0 citations
Open access Aug 2026

Mortality reduction with implanted defibrillator for primary prevention of sudden death after Myocardial Infarction: temporal trends in the PROFID study.

In this analysis including a large cohort of post-myocardial infarction patients with reduced LVEF, the estimated mortality reduction associated with primary prevention ICD implantation progressively decreased over time.

Alireza Sepehri Shamloo, T. Chiba, J. G. Tijssen et al. · 0 citations
Sep 2026

Comparison of Segmental Longitudinal Peak Strain Values in Patients with Non-Ischemic Dilated Cardiomyopathy

Although the AUC indicates moderate discriminative performance, regional strain analysis may serve as an adjunctive risk stratification tool alongside LVEF in this population, and may help identify patients who warrant further evaluation with advanced imaging modalities.

Ö. Kümet, F. Şaylık, T. Akbulut et al. · 0 citations
Open access Sep 2026

Predictive Value of the Electrical Risk Score for Ventricular Arrhythmias in Heart Failure Patients with Primary Prevention Implantable Cardioverter Defibrillators

The electrical risk score (ERS) was associated with ventricular arrhythmia-related ICD shocks in HF patients undergoing primary prevention ICD implantation and may identify patients at increased arrhythmic risk and guides follow-up and ICD management.

Pelin Aladağ, I. Erbay, N. E. Güdül et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.